DDInter1866 DDInter1676
A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Trifluoperazine {u} (Compound) resembles {v} (Compound) Clozapine
Trifluoperazine {u} (Compound) resembles {v} (Compound) Zuclopenthixol
Trifluoperazine {u} (Compound) binds {v} (Gene) ADRA1A
Trifluoperazine {u} (Compound) upregulates {v} (Gene) SREBF2
Trifluoperazine {u} (Compound) palliates {v} (Disease) schizophrenia
Trifluoperazine {u} (Compound) is included by {v} (Pharmacologic Class) Phenothiazines
Trifluoperazine {u} (Compound) downregulates {v} (Gene) PSMD2
Trifluoperazine {u} (Compound) causes {v} (Side Effect) Convulsion
Trifluoperazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magaldrate
Trifluoperazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sucralfate
Trifluoperazine (Compound) resembles Clozapine (Compound)
Trifluoperazine (Compound) resembles Zuclopenthixol (Compound)
Trifluoperazine (Compound) binds ADRA1A (Gene)
Trifluoperazine (Compound) upregulates SREBF2 (Gene)
Trifluoperazine (Compound) palliates schizophrenia (Disease)
Trifluoperazine (Compound) is included by Phenothiazines (Pharmacologic Class)
Trifluoperazine (Compound) downregulates PSMD2 (Gene)
Trifluoperazine (Compound) causes Convulsion (Side Effect)
Trifluoperazine may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Trifluoperazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate